Price Alert

Rhythm Pharmaceuticals In... (RYTM)

NASDAQ: RYTM · Real-Time Price · USD

99.02

1.79 (1.84%)

At close: Oct 03, 2025, 3:59 PM

Rhythm Pharmaceuticals Statistics

Share Statistics

Rhythm Pharmaceuticals has 66.42M shares outstanding. The number of shares has increased by 8.08% in one year.

Shares Outstanding	66.42M
Shares Change (YoY)	8.08%
Shares Change (QoQ)	4.4%
Owned by Institutions (%)	99.99%
Shares Floating	54.8M
Failed to Deliver (FTD) Shares	6
FTD / Avg. Volume	n/a

Short Selling Information

The latest short interest is 5.22M, so 7.86% of the outstanding shares have been sold short.

Short Interest	5.22M
Short % of Shares Out	7.86%
Short % of Float	10.08%
Short Ratio (days to cover)	8.57

Valuation Ratios

The PE ratio is -13.1 and the forward PE ratio is -51.82. Rhythm Pharmaceuticals's PEG ratio is -0.42.

PE Ratio	-13.1
Forward PE	-51.82
PS Ratio	26.24
Forward PS	21.2
PB Ratio	20.75
P/FCF Ratio	-29.98
PEG Ratio	-0.42

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Rhythm Pharmaceuticals.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.24, with a Debt / Equity ratio of 0.02.

Current Ratio	3.24
Quick Ratio	3.08
Debt / Equity	0.02
Debt / EBITDA	-0.02
Debt / FCF	-0.03
Interest Coverage	-12.89

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$459.81K
Profits Per Employee	$-920.86K
Employee Count	283
Asset Turnover	0.33
Inventory Turnover	0.71

Taxes

Income Tax	346K
Effective Tax Rate	-0.13%

Stock Price Statistics

The stock price has increased by 100.14% in the last 52 weeks. The beta is 2.24, so Rhythm Pharmaceuticals's price volatility has been higher than the market average.

Beta	2.24
52-Week Price Change	100.14%
50-Day Moving Average	96.61
200-Day Moving Average	69.66
Relative Strength Index (RSI)	47.64
Average Volume (20 Days)	739,955

Income Statement

In the last 12 months, Rhythm Pharmaceuticals had revenue of 130.13M and earned -260.6M in profits. Earnings per share was -4.21.

Revenue	130.13M
Gross Profit	116.76M
Operating Income	-265.5M
Net Income	-260.6M
EBITDA	-238.09M
EBIT	-239.65M
Earnings Per Share (EPS)	-4.21

Full Income Statement

Balance Sheet

The company has 89.14M in cash and 3.94M in debt, giving a net cash position of 85.2M.

Cash & Cash Equivalents	89.14M
Total Debt	3.94M
Net Cash	85.2M
Retained Earnings	-1.16B
Total Assets	372.73M
Working Capital	231.22M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -113.88M and capital expenditures 0, giving a free cash flow of -113.88M.

Operating Cash Flow	-113.88M
Capital Expenditures	n/a
Free Cash Flow	-113.88M
FCF Per Share	-1.87

Full Cash Flow Statement

Margins

Gross margin is 89.73%, with operating and profit margins of -204.04% and -200.27%.

Gross Margin	89.73%
Operating Margin	-204.04%
Pretax Margin	-200%
Profit Margin	-200.27%
EBITDA Margin	-182.97%
EBIT Margin	-204.04%
FCF Margin	-87.51%

Dividends & Yields

RYTM does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for RYTM is $110, which is 13.1% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$110
Price Target Difference	13.1%
Analyst Consensus	Strong Buy
Analyst Count	13

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	11.61
Piotroski F-Score	2